Facebook Inc’s initial public offering (IPO), plagued by trading errors and a share price drop of 16 percent, will push more individual investors out of a stock market that they already distrust after the financial crisis.
“This is clearly the latest in a long string of events that is eviscerating the confidence investors have in the market,” said Andrew Stoltmann, a Chicago attorney who represents retail investors. “The perception is Wall Street jiggered this IPO so the underwriters made money, Facebook executives made money and the small investor got left holding the bag.”
Individual buyers’ willingness to venture into stocks was undercut by difficulties in executing trades on the first day of trading on May 18, Facebook’s subsequent decline and questions as to whether the firm and underwriters selectively disclosed material and non-public information.
“If you have a lot of angry people out there, they’re going to express their anger in different ways,” said Steve Sosnick, equity risk manager for Timber Hill LLC, the market-making unit of Connecticut-based Interactive Brokers Group Inc. “One of them may be with their feet.”
The IPO produced the worst five-day return among the largest US deals of the past decade. The 13 percent decline through Thursday exceeded the 10 percent drop by MF Global Holdings Inc in its first five sessions. Visa Inc did best among the biggest deals, rising 45 percent.
Patricia Arroyo, 53, a psychologist and executive coach in Boston who manages her own investments, said: “What shakes my investor confidence more than the glitches is to see all the institutional investors, insiders and favored clients get all the advantages in these situations.”
After Facebook said on May 9 that growth in advertising had failed to keep up with user gains, analysts at some banks underwriting the deal cut their earnings estimates, people familiar with the process said. The new estimates were relayed to institutional investors.
US Federal securities regulators and the US Senate’s banking committee have said they will or may review the Facebook offering. Buyers of the stock have sued Facebook, the sale’s underwriters and NASDAQ OMX Group Inc, the exchange handling the listing. New York-based NASDAQ was overwhelmed by order cancelations and trade confirmations were delayed on the first day of trading.
Brokerages whose customers had trouble executing Facebook trades, including Boston-based Fidelity Investments and Charles Schwab Corp, said they are trying to resolve complaints.
“Fidelity senior management has been working with regulators, market makers and NASDAQ to represent all of our customers’ trading issues from May 18 and we will continue to do so in order to persuade NASDAQ to mitigate the impact on our customers,” Stephen Austin, a spokesman at Fidelity, said in a phone interview.
Despite trading problems and losses, many investors who have already purchased the stock are continuing to hold on, said John Dominic, vice president of trading for TradeKing, an online broker based in Fort Lauderdale, Florida.
“Most are probably taking a wait-and-see approach,” Dominic said.
‘OUT IN FRONT’: The new investment is part of MediaTek’s bid to expand revenue by 15 percent over the next three years from an estimated US$17 billion this year MediaTek Inc (聯發科) is to continue investing in the development of low-power technologies to maintain its leading position in the industry over the next 10 years, the Hsinchu-based chip designer said yesterday. This year, it would allocate US$3.3 billion to the research and development of technologies related to high-performance computing, low power and advanced chip packaging, MediaTek said. The investment is part of the chip designer’s efforts to enhance its technological capabilities and boost revenue. MediaTek aims to expand revenue by about 15 percent over the next three years from an estimated US$17 billion this year. “We are definitely out in front of
PharmaEssentia Corp (藥華醫藥) shares have jumped 80.56 percent since the company obtained a US polycythemia vera (PV) drug license for its new interferon drug Besremi (ropeginterferon alfa-2b-njft) on Nov. 12. Shares on Friday closed at NT$195 in Taipei trading, up from the stock’s closing price of NT$108 on Nov. 12. PV is a rare, chronic and life-threatening blood cancer linked to a stem cell mutation in the bone marrow that results in an overproduction of blood cells and places sufferers at risk of having a blood clot, stroke or heart attack. PharmaEssentia is preparing to make Besremi available in the US in the
The US$410 DeliSofter pot looks much like the rice cookers ubiquitous in Japanese households and it does prepare rice in 24 minutes. However, this invention of two Panasonic Corp engineers is designed to do more and help people with swallowing difficulties. The two women led the creation of a spin-off company, Gifmo Co, to sell the specialized steam cooker, which they say can turn fried chicken soft enough to be sliced with a potato chip. The machine works by first cutting into food with a series of blades and then subjecting it to extremely high pressure at a temperature of 120°C,
Industrial metals plunged and gold rallied as the emergence of a fast-spreading and highly mutated SARS-CoV-2 strain sparked a sell-off across financial markets. Base metals, including copper and aluminum, fell more than 3 percent in London as investors weighed the risk that the new variant identified in South Africa might spur fresh outbreaks and derail growth in the world’s leading industrial economies. Scientists say it carries a high number of mutations that could make it more effective at evading existing vaccines. The new strain creates fresh risks to the outlook for metals demand, imperiling a recent rebound in prices driven by chronic